26 June 2024
Current Oncology | Cancer Immunotherapy Awareness Month
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
Cancer Immunotherapy Awareness Month, taking place in June, is dedicated to raising awareness of the importance and potential of immunotherapy in the treatment of cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of cancer immunotherapy, published in Current Oncology (ISSN: 1718-7729). We hope that this announcement will provide useful information regarding this field.
“Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29, 1559-1574. https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131
“The Role of Immunotherapy in Pancreatic Cancer”
by Reetu Mukherji, Dipanjan Debnath, Marion L. Hartley and Marcus S. Noel
Curr. Oncol. 2022, 29, 6864-6892. https://doi.org/10.3390/curroncol29100541
Available online: https://www.mdpi.com/1718-7729/29/10/541
“Immunotherapy in Squamous Cell Cancer of the Esophagus”
by Peter Thuss-Patience and Alexander Stein
Curr. Oncol. 2022, 29, 2461-2471. https://doi.org/10.3390/curroncol29040200
Available online: https://www.mdpi.com/1718-7729/29/4/200
“Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma”
by Jong Chul Park, Hari N. Krishnakumar and Srinivas Vinod Saladi
Curr. Oncol. 2022, 29, 4185-4198. https://doi.org/10.3390/curroncol29060334
Available online: https://www.mdpi.com/1718-7729/29/6/334
“Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients”
by Justin Tong, Adi Kartolo, Cynthia Yeung, Wilma Hopman and Tara Baetz
Curr. Oncol. 2022, 29, 7953-7963. https://doi.org/10.3390/curroncol29100629
Available online: https://www.mdpi.com/1718-7729/29/10/629
“Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review”
by Raida M. Khwaja and Quincy S.-C. Chu
Curr. Oncol. 2022, 29, 479-489. https://doi.org/10.3390/curroncol29020043
Available online: https://www.mdpi.com/1718-7729/29/2/43
The list of relevant Special Issues is as follows:
Immunotherapy for Gastrointestinal Cancer
Guest Editor: Dr. Patrick M. Boland
Available online: https://www.mdpi.com/journal/curroncol/special_issues/Immunotherapy_GI
Immune Checkpoint Inhibitors in Cancer Therapy: State of the Art and Future Perspectives
Guest Editors: Dr. Aparna Jayachandran, Prof. Dr. George Kannourakis and Dr. Prashanth Prithviraj
Available Online: https://www.mdpi.com/journal/curroncol/special_issues/Immune_Checkpoint_Inhibitors_Cancer_Therapy
You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.
Current Oncology Editorial Office